X
[{"orgOrder":0,"company":"Alligator Bioscience","sponsor":"Orion Pharma","pharmaFlowCategory":"D","amount":"$552.8 million","upfrontCash":"Undisclosed","newsHeadline":"Alligator Bioscience announces Immuno-oncology Research Collaboration and License Agreement with Orion Corporation","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery Platform","country":"SWEDEN","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2021","url1":"","url2":"","graph1":"Large molecule","graph2":"Alligator Bioscience"},{"orgOrder":0,"company":"BioInvent","sponsor":"Exelixis","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Exelixis and BioInvent Establish Exclusive Option and License Agreement to Develop Novel Antibody-Based Immuno-Oncology Therapies","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery Platform","country":"SWEDEN","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2022","url1":"","url2":"","graph1":"Large molecule","graph2":"BioInvent"}]
Find Clinical Drug Development Pipelines & Deals | PipelineProspector
Filters
Details:
Target and antibody discovery will be performed using BioInvent’s proprietary n-CoDeR ® antibody library and patient-centric F.I.R.S.T™ screening platform, which together allow for parallel target and antibody discovery.
Lead Product(s):
Antibody-drug Conjugate
Therapeutic Area: Oncology
Product Name: Undisclosed
Highest Development Status: Discovery Platform
Product Type: Large molecule
Partner/Sponsor/Collaborator:
Exelixis
Deal Size: Undisclosed
Upfront Cash: Undisclosed
Deal Type: Licensing Agreement
June 16, 2022
Details:
Under the agreement, Alligator Bioscience will employ its proprietary phage display libraries and RUBY™ bispecific platform to develop immuno-oncology product candidates based on design criteria identified by Orion.
Lead Product(s):
Bispecific Antibody
Therapeutic Area: Oncology
Product Name: Undisclosed
Highest Development Status: Discovery Platform
Product Type: Large molecule
Partner/Sponsor/Collaborator:
Orion Pharma
Deal Size: $552.8 million
Upfront Cash: Undisclosed
Deal Type: Collaboration
August 18, 2021